The latecomer leukemia treatment ‘Bosulif’ is attempting to receive reimbursement in Korea.

According to industry sources, Pfizer Korea submitted an application for its Chronic Myelogenous Leukemia (CML) treatment Bosulif (bosutinib), and is receiving a review for its reimbursement.

The drug, which was approved in January in Korea, was rather late in entering Korea after it was approved by the U.S. FDA in 2012.

Bosulif is a 2nd generation targeted anticancer therapy like Novartis Kroea’s ’ ‘Tasigna (nilotinib),’ BMS Korea’s ‘Sprycel (dasatinib),’ Il-Yang Pharamceutical’s ‘Supect (radotinib)’. With so many drugs already on the market, no major difficulties are